15.0 
REFERENCES 
1. Rosenberg SA. Immunotherapy of patients with advanced cancer using interleukin- 
2 alone or in combination with lymphokine-activated killer cells. DeVita VT, 
Heilman S, and Rosenberg SA (eds.). Important Advances in Oncology 1988 . 
Philadelphia, PA: JP Lippincott, 1988, p.217. 
2. Parkinson DR, Fisher RI, Rayner AA et al. Therapy of renal cell carcinoma with 
interleukin-2 and lymphokine-activated killer cells: phase II experience with a 
hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol 
8: 1630; 1990. 
3. American Cancer Society. Cancer Facts. 1989. 
4. Comis RL. DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer 
Treat Rep:609: 165; 1976. 
5. Carbone PP, Costello W. Eastern Cooperative study groups with DTIC 
(NSC-45388). Cancer Treat Rep:60: 193; 1976. 
6. Luikart SD, Kennealey GT, and Kirkwood JM. Randomized phase III trial of 
vinblastine, bleomycin and cisdichlorodiammine-platinum versus dacarbazine in 
malignant melanoma. J Clin Oncol:2: 164; 1984. 
7. Costanza ME, Nathanson L, Schoenfeld D et al. Results with methyl-CCNU and 
DTIC in metastatic melanoma. Cancer:40: 1010; 1977. 
8. Bellet RE, Mastrangelo MJ, Berd D et al. Chemotherapy of metastatic malignant 
melanoma. In: Clark WH Jr, Goldman LL, and Mastrangelo MJ (eds.). Human 
malignant melanoma . New York: Grune and Stratton, 1979, p.325. 
9. Creagan ET, Ahmann DL, Green SI et al. Phase II study of recombinant leukocyte 
A interferon in disseminated malignant melanoma. Cancer 54:2844; 1984. 
10. Vadhan-Raj S, Cordon-Cardo C, Carswell E et al. Phase I trial of a mouse 
monoclonal antibody against GD3 ganglioside in patients with melanoma: Induction 
of inflammatory responses at tumor sites. J Clin Oncol 6: 1636; 1988. 
11. Rosenberg SA. Special Report: Observations on the systemic administration of 
autologous lymphokine-activated killer cells and recombinant interleukin-2 in 
patients with metastatic cancer. NEJM 3 13: 1485-96; 1985. 
Recombinant DNA Research, Volume 15 
[905] 
